

Supporting Information for

**Fluoride as An Inducible DNA Cross-linking Agent for New
Antitumor Prodrug**

**Jun Wu,^a Rong Huang,^a Tianlu Wang,^a Xi Zhao,^a Wanyi Zhang,^a Xiaocheng
Weng,^a Tian Tian,^a Xiang Zhou^{ab*}**

College of Chemistry and Molecular Sciences, Key Laboratory of Biomedical
Polymers of Ministry of Education, Wuhan University, Hubei, Wuhan, 430072, P. R.
of China, Corresponding Author Email Address: xzhou@whu.edu.cn

Table of Contents

Apparatus and Materials.....	3
General procedure for the synthesis of compound 1	3
Figure S1 ICL of compound 2 with different fluoride concentration.....	6
Figure S2 ICL of compound 2 with different anion selectivity	6
Figure S3 Cell viability in the presence of 2 at different concentrations.....	7
Figure S4 Cell viability in the presence of fluoride at different concentrations.....	7

Apparatus


^1H and ^{13}C NMR spectra were recorded on Varian Mercury 300 spectrometers, respectively. HRMS were recorded on a Bruker APEX IV (7.0 T).

Materials

All solvents and reagents were commercially available and used without further purification unless for special needs: MEM (HyClone, Thermo Scientific), fetal bovine serum (FBS, HyClone), penicillin and streptomycin (Invitrogen), MTT (Sigma), and propidium iodide (Sigma-Aldrich). HeLa cells were purchased from China Center for Type Culture Collection.

Synthesis experiments

General information: Unless otherwise specified, chemicals were purchased from Alfa Aesar or Sigma-Aldrich and were used as received without further purification.



Scheme S1. Synthesis of compound **1**. a) *tert*-Butyldimethylsilyl chloride, chloroform, RT; b) sodium borohydride, ethanol, RT; c) TFA, THF; d) lithium bromide, THF; e) *N*-methyldiethanolamine, chloroform; f) thionyl chloride, RT.

Synthesis of compound **1**

4-(*tert*-Butyldimethylsilyloxy)benzaldehyde (1b**)**¹: To a mixture of **1a** (1.2 g, 10 mmol) in 50 mL chloroform was added *tert*-butyldimethylsilyl chloride (1.8 g, 12 mmol), TEA (1 mL), the reaction mixture was stirred at room temperature for 12 h. The mixture was diluted by DCM, washed by H₂O (3×50 mL) and dried with anhydrous Na₂SO₄. The mixture was evaporated and the residue was subjected to column chromatography on silica gel with 0–5% DCM in hexane to give the desired

product **1b** as a white solid (1.9 g, 86%). ¹H NMR (300 MHz, CDCl₃): δ = 1.38 (s, 4 H), 3.08 (s, 9 H), 7.26 (s, 2 H), 11.97 ppm (s, 1 H).

4-(tert-Butyldimethylsilyloxy)phenylmethanol (1c)¹ : NaBH₄ (0.28 g, 7.5 mmol) was added to a mixture of **1b** (1.2 g, 5 mmol) in 50 mL ethanol. The mixture was stirred at room temperature for 2 h. Then the reaction mixture was evaporated and diluted with chloroform, washed by H₂O (3 × 50 mL) and dried with anhydrous Na₂SO₄ respectively. The solution was evaporated and the residue was subjected to column chromatography on silica gel with ethyl acetate/cyclohexane (1: 5, v/v) as eluent to get the desired product as a white solid **1c** (0.9 g, 90%). ¹H NMR (300 MHz, CDCl₃): δ = 0.02 (s, 4 H), 0.89 (s, 9H), 4.87(s, 2 H), 5.31(s, 1 H), 6.70 (s, 2 H), 7.06 ppm (s, 2 H).

4-(tert-Butyldimethylsilyloxy)benzyl 2,2,2-trifluoroacetate (1d)¹: TFA (1 ml, 1.2 mmol) was added to a mixture of **1c** (0.24 g, 1 mmol) in 30 mL THF. The reaction mixture was refluxed for 0.5 h and then mixture was diluted by chloroform (30 mL), washed by H₂O (3 × 50 mL). After the isolated solution was dried with anhydrous Na₂SO₄, it was evaporated and the residue was subjected to column chromatography on silica gel with ethyl acetate/cyclohexane (1:10, v/v) as eluent to get the desired product **1d** as a yellow oil (0.23 g, 70%). ¹H NMR (300 MHz, CDCl₃): δ = 0.06 (s, 4 H), 1.23(s, 9H), 4.98(s, 2 H), 7.06(s, 2 H), 7.36 ppm (s, 2 H).

4-(tert-Butyldimethylsilyloxy)benzylbromide (1e)¹: To a mixture of **1d** (0.34 g, 1 mmol) in 30 mL THF was added LiBr (0.1 g, 1.2 mmol), the reaction mixture was refluxed for 20 h. After the mixture was diluted by chloroform (30 mL), washed by H₂O (3 × 50 mL) and dried with anhydrous Na₂SO₄, the solution was evaporated and the residue was subjected to column chromatography on silica gel with ethyl acetate/cyclohexane (1:10, v/v) as eluent to get the desired product **1e** as a yellow solid (0.23 g, 78%). ¹H NMR (300 MHz, CDCl₃): δ = 0.21 (s, 4 H), 0.98 (s, 9 H), 4.56 (s, 2 H), 6.86 (s, 2 H), 7.16 ppm (s, 2 H).

4-Ditert-butylmethylsilyloxy-N, N'-bis(2-hydroxyethyl)-N, N'-dimethylphenyl (1f) : A solution of 4-(tert-butylmethylsilyloxy)benzylbromide (**1e**) (0.15 g, 0.5 mmol) and N-methyldiethanolamine (0.12 g, 1 mmol) in chloroform (40 mL) was refluxed for overnight. After filtration, the crude product was recrystallized by ethanol and ethylether for several times. The product **1f** was obtained as a white solid (0.21 g, 90%). ¹H NMR (300 MHz, DMSO-*d*₆): δ = 0.82 (s, 4 H), 0.81(s, 9 H), 2.83(s, 3 H), 3.17-3.37 (m, 4 H), 3.76 (s, 4 H), 4.49 (s, 2 H), 5.20 (s, 2 H), 6.80 (s, 2 H), 7.35 ppm (s, 2 H). ¹³C NMR (DMSO-*d*₆, 600 MHz): δ 153.5, 129.6, 125.5, 120.3, 66.3, 64.5, 48.1, 25.5, 17.3, -4.03 ppm. ESI-MS found m/z = 340.9 [M-Br].

4-Ditert-butylmethylsilyloxy-N, N'-bis(2-chloroethyl)-N, N'-dimethylphenyl (1) : A solution of 4-ditert-butylmethylsilyloxy-N, N'-bis(2-hydroxyethyl)-N,

N'-dimethylphenyl (**1f**) (0.1 g, 0.20 mmol) in CH₂Cl₂ (20 mL) was slowly added dropwise to thionyl chloride (2 mL) in ice-water bath, then stirred at r. t. for 2 days. After evaporated, the residue was recrystallized with CH₃OH/Et₂O several times, then the deaired product **1** was obtained (0.086 g, 85%). ¹H NMR (300 MHz, DMSO-*d*₆): δ = 0.23 (s, 4 H), 0.96 (s, 9H), 3.07 (s, 3 H), 3.69-3.96 (m, 4H), 4.18 (s, 4 H), 4.72 (s, 2 H), 7.16 ppm (s, 2 H); ¹³C NMR (DMSO-*d*₆, 600 MHz): δ151.5, 130.6, 126.5, 119.3, 65.3, 63.5, 46.1, 23.5, 16.3, -4.09 ppm. HRMS-ES (*m/z*) [M-Br]⁺ calcd. For C₁₈H₃₂Cl₂NOSi, 376.1625; found, 376.1624

DNA experiments:

General Information: Plasmid DNA (pBR322) was purchased from Fermentas Co., Ltd. The DNA oligonucleotide was purchased from Takara BIO Co.Ltd., with the 5'-terminus fluorolabeled with TAMRA.

General protocol for alkaline agarose gel electrophoresis:

See reference 2.

Cross-linking of DNA oligonucleotide by compounds:

Cross-linking reaction was carried out in a volume of 10 μL containing 5 μM selective 5'-terminus fluoro-labeled oligonucleotide, 10 mM KF, 10 mM phosphate buffer (pH = 7.4) and 1 mM compound. The mixture was incubated at 37 °C for 3 h. Then the solution was mixed with 10 μL formamide deionized to the final volume of 20 μL. The residue was took out and then analyzed by a 20% denaturing polyacrylamide electrophoresis. The cross-linking products of compounds **1** and **2** with oligonucleotide were produced follow the same protocol mentioned as above.

Piperidine treatment

The cross-linked products were isolated by following procedures: first, ethanol and sodium acetate/acetic acid buffer (pH = 5) at -20 °C for one night, then the mixture was centrifugated 12000 rpm at 4 °C for 20 min, dried and treated with 100 μL 1 M piperidine for 30 min at 90 °C. After stored and precipitated by ethanol at -20 °C for one night, the DNA product fragments were then obtained and further dissolved it in formamide deionized. The cross-linking results were analyzed by polyacrylamide gel electrophoresis under denaturing conditions.




Figure S1. Cross-linking results of compound 2 with different fluoride concentration. lane 1: 0.5 μ g pBR322 control ; lane 2: 0.5 μ g pBR322 + 50 μ M compound 2 + 50 μ M KF; lane 3 0.5 μ g pBR322 + 50 μ M compound 2 + 100 μ M KF; lane 3 : 0.5 μ g pBR322 + 50 μ M compound 2 + 500 μ M KF; lane 4: 0.5 μ g pBR322 + 50 μ M compound 2 + 1 mM KF.




Figure S2. Cross-linking results of compound 2 with different anion selectivity. lane 1: 0.5 μ g pBR322 control ; lane 2: 0.5 μ g pBR322 + 50 μ M compound 2 + 10 mM IO_4^- ; lane 3 0.5 μ g pBR322 + 50 μ M compound 2 + 10 mM OCl^- ; lane 4 : 0.5 μ g pBR322 + 50 μ M compound 2 + 10 mM Br^- ; lane 5: 0.5 μ g pBR322 + 50 μ M compound 2 + 10 mM I^- . lane 6: 0.5 μ g pBR322 + 50 μ M compound 2 + 10 mM KF.




Figure S3. Cell viability in the presence of **2** at different concentrations (50 nM-100 μM) with 100 μM fluoride. The data were obtained through MTT assay and presented as mean ± SD (n= 3).




Figure S4. Cell viability in the presence of fluoride at different concentrations (10 μM-50mM). The data were obtained through MTT assay and presented as mean ± SD (n= 3).

Reference

- 1 K. Kopka , A. Faust , P. Keul , S. Wagner , H. Breyholz , C. Höltke , O. Schober , M. Schäfers , and B. Levkau *J. Med. Chem.* 2006, **49**, 6704–6715
- 2 P. Wang, R. P. Liu, X. J. Wu, H. J. Ma, X. P. Cao, P. Zhou, J. Y. Zhang, X. C. Weng, X. L. Zhang, J. Qi, X. Zhou, L. H. Weng, *J. Am. Chem. Soc.* 2003, **125**, 1116-1117.